As society comes to grips with the personal, economic and social effects of Alzheimer's disease, the FDA remains determined to facilitate the discovery of effective treatments, FDA Commissioner Dr. Margaret Hamburg writes. The agency is participating in efforts to create a national plan to address the Alzheimer's disease crisis and is partnering on public-private initiatives and with advocacy groups and consortia in the Alzheimer’s community, she writes.

Full Story:
FDA Voice blog

Related Summaries